← Evidence map

ArticlePloS one2026

Imipenem/cilastatin/relebactam treatment of hospital-acquired/ventilator-associated bacterial pneumonia caused by imipenem-nonsusceptible pathogens: Subgroup analysis and molecular characterization of isolates from the RESTORE-IMI 2 clinical study.

Katherine Young et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

The trial

NCT02493764phase 3537 enrolled2015

Imipenem/cilastatin/relebactam treatment of hospital-acquired/ventilator-associated bacterial pneumonia caused by imipenem-nonsusceptible pathogens: Subgroup analysis and molecular characterization of isolates from the RESTORE-IMI 2 clinical study. | OpenQuestion